Testing several treatment options for new or returning glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- Your tumor has been confirmed as grade 4 glioblastoma (including a type called gliosarcoma) and is IDH-wild type.
- You can provide tumor tissue from your surgery or biopsy for testing.
- Your overall strength is sufficient (Karnofsky score): at least 60% if newly diagnosed, at least 70% if the cancer has returned.
- If the cancer has returned, you must have scans showing progression, confirmed by two scans at the right times.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial offers expanded access to an experimental treatment (RZ-001) for people with recurrent glioblastoma (a type of brain cancer) that has grown again after initial treatment. It is for those who cannot join other clinical trials and aims to provide possible treatment options when standard ones have failed.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.